Renovorx engages oklahoma university (ou) health as first clinical site in preparation for the pivotal phase iii cougar clinical trial in bile duct cancer

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the expansion of their clinical development pipeline in preparation for the commencement of a second phase iii trial. the cougar trial will evaluate renovogem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma (.
RNXT Ratings Summary
RNXT Quant Ranking